A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > BUSINESS
BUSINESS
- I/O in Lung Cancer - 6: Analyst Says US Merck Claimed Victory in 2018 ASCO Confab, Applauds Trial Designs for Keytruda
September 26, 2018
- Takeda’s Brigatinib Snags European Panel OK for 2nd Line ALK-Positive NSCLC
September 26, 2018
- Xtandi Gets CHMP Backing for Additional CRPC Indication
September 26, 2018
- DS-8201 Shows Positive PI Study Data for NSCLC: Daiichi Sankyo
September 26, 2018
- European Panel Backs Approval of Kyowa Kirin’s Mogamulizumab for Mycosis Fungoides, Sézary Syndrome
September 26, 2018
- Santen Files for Japan Approval of Anti-Allergy Eye Drop
September 26, 2018
- Daiichi Sankyo, Pfizer Grab Japan Approval for Herceptin Biosimilars
September 25, 2018
- AMED Backs Project for Development of Familial Adenomatous Polyposis Therapy Applied by FunPep, 3 Universities
September 25, 2018
- Fujifilm Kyowa Kirin, Mylan Bag EU Approval of Humira Biosimilar
September 25, 2018
- Daiichi Sankyo Teams Up with US Merck’s Subsidiary for Clinical Research of DS-8201/Keytruda Combo
September 25, 2018
- Astellas to Create New Business beyond Core Prescription Drug Business, Aims to Launch Several Products by FY2020
September 21, 2018
- Meiji Seika Pharma Commences Shipment of KM Biologics’ Flu Vaccine
September 21, 2018
- Roxadustat Hit Goal in CKD Patients with Anemia Not on Dialysis in Multinational PIII Study: Astellas
September 21, 2018
- Meiji Files Aricept Generic for Lewy Body Dementia to Win Full Indications
September 21, 2018
- Growing Number of Drug Makers Introducing LGBT-Friendly Policies
September 20, 2018
- Sosei, Allergan Suspend Joint Clinical Development of AD Therapy due to Unexpected Toxicology Findings
September 20, 2018
- Otsuka Pharmaceutical Factory Accuses AY Pharmaceuticals, Yoshindo for Patent Infringement on Transfusion Product
September 20, 2018
- Ono, US Bioventure Fate Therapeutics Hook Up for CAR-T Therapies
September 19, 2018
- Nichi-Iko to Copromote 5 Elmed Eisai Products from October
September 18, 2018
- Astellas Joins Hands with Gene Therapy Biotech for ALS Treatment Program
September 18, 2018
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…